Market Access Views & Analysis

Views & Analysis

Improving access and reimbursement for specialty therapies

As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more

Views & Analysis

Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.

Views & Analysis

Breaking policy and perceptual barriers: Biosimilars

Experts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted the adoption of biosimilars.

Views & Analysis

Teva’s Kim Innes on shaping the post-COVID future with the N...

Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the

Views & Analysis